Manipulation of the mouse genome by site-specific mutagenesis has been extensively used to study gene function and model human disorders. Mouse models of myotubular myopathy (XLMTM), a severe congenital muscular disorder due to loss-of-function mutations in the MTM1 gene, have been generated by homologous recombination and shown that myotubularin is essential for skeletal muscle. However, since the Mtm1 deletion occurred constitutively or shortly after birth in these mice, it is not known whether myotubularin is required during adulthood, an important issue in the context of not only muscle biology but also therapies. To delete the Mtm1 gene in adult muscle fibers, we constructed a recombinant adeno-associated vector (AAV) that expresses the Cre recombinase under the muscle-specific desmin promoter. We report that a single injection of this vector into muscles of 3-month-old Mtm1 conditional mice leads to a myotubular myopathy phenotype with myofiber atrophy, disorganization of organelle positioning, such as mitochondria and nuclei, T-tubule defects and severe muscle weakness. In addition, our results show that MTM1-related atrophy and dysfunction correlate with abnormalities in satellite cell number and markers of autophagy, protein synthesis and neuromuscular junction transmission. The expression level of atrogenes was also analyzed. Therefore, we provide a valuable tissue model that recapitulates the main features of the disease, and it is useful to study pathogenesis and evaluate therapeutic strategies. We establish the proof-of-concept that myotubularin is required for the proper function of skeletal muscle during adulthood, suggesting that therapies will be required for the entire life of XLMTM patients.
INTRODUCTION
X-linked myotubular myopathy (XLMTM, OMIM 310400) is the most severe and frequent form of a group of disorders named centronuclear myopathies. XLMTM patients are already affected during fetal life, they manifest a reduction of movements during gestation and present at birth with a myopathy that appears nonprogressive (1 -3) . They have generalized muscle weakness and hypotonia, leading to respiratory failure, and many of them die within the first years of life despite intensive medical care. Atypical, less severe forms of myotubular myopathy also exist in males and females with mild symptoms during infancy that worsen after the first or second decades (4) . Skeletal muscles from patients contain small fibers with altered distribution of organelles, such as nuclei and mitochondria, which are typically located in the center of fibers or, in milder cases, disposed as a necklace in the subsarcolemal region (4, 5) . The disease is due to loss-of-function mutations in the ubiquitously expressed MTM1 gene that encodes a phosphoinositide phosphatase named myotubularin (6) . Animal models of the disease currently exist in zebrafish, mouse and dog (7) (8) (9) (10) . Studies from these models have shown that, in skeletal muscle, myotubularin plays a role in various processes, including T-tubule * To whom correspondence should be addressed at: Généthon, 1 bis, rue de l'Internationale, 91000 Evry, France. Tel: +33 169472828; Fax: +33 160778698; Email: abujbello@genethon.fr and intermediate filament organization, excitation-contraction coupling, neuromuscular junction (NMJ) transmission and satellite cell survival and proliferation (11 -14) . Myotubularin function appears essential during late stages of muscle formation and growth, but it is currently unknown whether it is also required in muscle during adult life.
Spacio-temporal gene inactivation is traditionally obtained by crossing a mouse line that contains two LoxP sites flanking an essential exon of the gene of interest and inducible Cre transgenic mice (15) . However, adeno-associated vectors (AAVs) represent a powerful tool to express transgenes in vivo and several serotypes transduce with high-efficiency skeletal muscle (16 -18) . Since previous studies have shown that AAV can efficiently deliver the Cre recombinase to tissues, such as brain, and mediate conditional gene modification (19) , we used this alternative approach to inactivate myotubularin in adult muscle.
In the present study, we report that intramuscular delivery of Cre-encoding AAV viral particles into Mtm1L2 conditional mice leads to extensive recombination and Mtm1 exon 4 deletion in targeted muscles. Our results demonstrate that AAV-injected muscles from adult mice have reduced levels of myotubularin and develop a progressive centronuclear myopathy with severe muscle weakness that recapitulates the hallmarks of the disease. Furthermore, these muscles reproduce known molecular and cellular mechanisms involved in XLMTM pathogenesis, such as T-tubule disorganization, a reduction in the number of Pax7 + satellite cells and increased expression of acetylcholine receptor subunits. Altogether, these findings describe for the first time that MTM1 is essential in skeletal muscle during adulthood, and provide a novel tissue model of myotubular myopathy.
RESULTS

Generation of an AAV vector for site-specific Mtm1 deletion in muscle
To induce a somatic mutation in the Mtm1 gene during postnatal life, we used a conditional Mtm1L2 mouse line that contains constitutively two LoxP sites around Mtm1 exon 4 (8) and generated a muscle-tropic AAV1 vector that carries the Cre recombinase under the desmin promoter to restrict expression to muscle. The N-terminal part of Cre was fused to green fluorescent protein (eGFP) to better visualize the recombinase in tissues (AAV-eGFP/Cre, Fig. 1A) .
We explored the efficacy of this novel strategy by local administration of 3 × 10 9 viral genomes (vg) of AAV-eGFP/Cre into the tibialis anterior (TA) muscle of 3-month-old Mtm1L2 and wild-type (WT) males. The contralateral muscle was injected with phosphate-buffered saline (PBS) as an internal control. We monitored the excision of Mtm1 exon 4 and 3 months later by PCR amplification of genomic DNA and western blot analysis of myotubularin protein level. Figure 1B shows that AAV-derived eGFP/Cre recombinase was indeed present in injected TA muscles and located in nuclei of muscle fibers (Supplementary Material, Fig. S1 ). Cre-mediated deletion of Mtm1 exon 4 occurred only in muscles from Mtm1L2 mice but not in WT animals (Fig. 1C) . Since absence of this exon in the mRNA results in a frameshift and premature stop codon, this muscle-specific mutation led to a strong reduction of myotubularin protein.
The level of MTM1 in Cre-injected floxed TA muscle dropped to 20% of endogenous levels (Fig. 1D) .
Deletion of the Mtm1 gene in a mature muscle reproduces the pathological hallmarks of myotubular myopathy
To evaluate the consequences of myotubularin deficiency in skeletal muscle from adult mice, the histological aspect of muscles from Mtm1L2 mice was analyzed 3 and 6 months after AAV-eGFP/Cre delivery. Figure 2A shows that deletion of Mtm1 exon 4 in TA led to a progressive reduction in muscle mass (47.5 + 1.4 mg at 3 months and 32.4 + 2.0 mg at 6 months post-injection compared with about 65 mg in control muscles) that correlated with a decrease in the volume of myofibers. Indeed, the diameter of Mtm1L2 muscle fibers was reduced by 30% (26.3 + 1.5 mm) and 55% (17.5 + 1.2 mm) 3 and 6 months after vector administration, respectively (Fig. 2B) . The curves reflecting the distribution of myofiber diameters shifted progressively to the left upon Cre recombinase expression. Accordingly, the percentage of fiber with their minor diameter ,20 mm shifted from 3.7% in the PBS-injected Mtm1L2 population to 36.7% at 3 months and 74.0% at 6 months after AAV1-eGFP/Cre injection (Fig. 2C) . No changes in myofiber morphology were observed upon vector delivery in WT animals.
Since organelles such as nuclei, mitochondria and T-tubules are abnormally located within myotubularin-deficient muscle fibers in both patients and constitutive Mtm1 KO mice, and these pathological features represent hallmarks of XLMTM pathology, we analyzed the distribution of these organelles in Mtm1-deleted muscle fibers from TA by hematoxylineosin (HE), nicotinamide adenine dinucleotide tetrazolium reductase (NADH-TR) and immunofluorescence stainings. Myofibers with internal nuclei were present in mutant muscle and increased significantly during disease progression, reaching 15.7% 6 months after vector injection (Fig. 2D ). Abnormal subsarcolemmal (necklace) and central accumulation of oxidative enzyme activity, which mainly reflects mitochondria positioning, was frequently observed in Mtm1-deleted muscle fibers (Fig. 3A) . Finally, alterations in the distribution of immunolabeled dihydropyridine receptors (DHPRa), a marker of T-tubules, were also present in Mtm1L2 myofibers at both 3 and 6 months post-injection compared with WT muscles (Fig. 3A) . At late stages of disease progression (6 months), DHPRa distribution was frequently anarchical, with aggregates inside fibers, and accumulated at the sarcolemma. We further analyzed the morphology of T-tubules at the ultrastructural level by electron microscopy using the selective potassium ferrocyanide staining procedure. As previously reported in constitutive Mtm1 KO muscle (11) , in addition to T-tubules, tubules with abnormal longitudinal orientation (L-tubules) that are aligned to the direction of myofibrils were observed in TA muscle fibers after AAVmediated myotubularin deficiency (Fig. 3B) . About 80% of abnormal T-tubules were found in muscle fibers 6 months after Mtm1 deletion.
Human Molecular
Mtm1 mutagenesis in adult mice leads to a severe reduction of muscle force
Muscle weakness is a constant sign of myotubularin deficiency; we therefore evaluated the strength of muscles after AAV-induced Mtm1 deletion in adult mice. Briefly, 3 × 10 9 vg of AAV1-eGFP/Cre were injected into the anterior compartment of the distal hindlimb, which includes the extensor digitorum longus (EDL) muscle, of 3-month-old Mtm1L2 and WT males. Like TA, Cre-injected Mtm1L2 EDL showed a progressive decrease in muscle mass compared with PBS-injected contralateral muscles (13.2 + 0.7 mg at 3 months post-injection versus 16.4 + 0.2 mg in controls, n ¼ 9, and 9.0 + 0.7 mg at 6 months versus 15.3 + 0.6 mg in controls, n ¼ 7) (Fig. 4A) . The total and specific isometric forces of isolated EDL muscles were measured during disease evolution. The total strength was already reduced by 35% at 3 months post-injection, and further decreased by 85% at 6 months ( Fig. 4B ). This decrease in muscle strength is not only a consequence of muscle mass reduction, but it is mainly due to the lower intrinsic force of myofibers, as the specific strength of mutant EDL muscle was also decreased by 72% 6 months after vector delivery (10.4 + 2.4 mN/mg compared with 29.9 + 1.4 mN/mg in controls, n ¼ 7) (Fig. 4C) .
Altogether, these results show that deletion of the Mtm1 gene in muscle fibers during adulthood leads to a progressive 
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Human Molecular Genetics, 2013, Vol. 22, No. 9 muscular disease that recapitulates the pathological features and strength deficits of myotubular myopathy.
Mechanisms involved in MTM1-related muscle atrophy during adulthood
Since myotubularin deficiency in adult mice results in muscle atrophy, we evaluated known molecular and cellular mechanisms involved in XLMTM-related hypotrophy (13, 14) and investigated the status of other pathways implicated in muscle mass regulation such as autophagy, protein synthesis and the ubiquitin -proteasome system (UPS) (20, 21) . First, we monitored the number of Pax7-positive cells in muscle, a marker of satellite cells, which was recently shown to decrease in Mtm1 KO (also named Mtm1d4) mice during disease progression (14) . We found a striking reduction in the number of satellite cells in TA muscle already 3 months after Cremediated Mtm1 deletion, and at 6 months, when atrophy was well established, Pax-7 positive cells were decreased by 90% compared with WT values (Fig. 5A) . Second, we examined the expression of several NMJ-associated transcripts, the acetylcholine receptor subunits (Chrng, Chrna, Chrnd and Chrne). Similar to previous results in Mtm1 KO mice, which manifest an NMJ transmission phenotype (13), there was a significant increase in Chrna, Chrnd, Chrne and Chrng mRNA levels in myotubularin-deficient TA muscle, suggesting that defects in NMJ transmission may also be present in this muscle and contribute to atrophy and dysfunction. This increase was progressive and correlated with disease evolution (Fig. 5B) . However, we did not find major abnormalities in the ultrastructure of NMJs (data not shown). We assessed the status of autophagy in mutant muscles first by analyzing the expression level of several genes involved in this pathway (Atg4b, Atg12l, Beclin, Bnip3L, Gabarapl1, LC3b and PI3K III). We found an upregulation of Gabarapl1 and LC3b mRNA level in TA of 4-week-old KO mice by 2.6-and 1.6-folds, respectively, but not in muscle after Cremediated Mtm1 deletion muscle, in which most of these transcripts remained unchanged or decreased at 3 and 6 months post-injection (Supplementary Material, Fig. S2 ). While preparing this manuscript, Fetalvero et al. (22) reported impaired autophagy and aberrant mTORC1 signaling in Mtm1 null mice. We therefore further explored these pathways by western blot analysis and measured LC3-I, LC3-II and p62 in extracts of Cre-induced mutant TA muscle. The levels of LC3-I and LC3-II were increased by 2-folds in myotubularin-deficient muscle compared with WT (Fig. 5C ). The elevation of p62, an LC3-interacting protein, did not reach statistical significance. Concerning the status of protein synthesis and mTORC1 signaling, like in muscles from KO mice, a marked increase of phosphorylated S6 and 4EBP1 was observed in TA muscle 6 months after Mtm1 deletion. Importantly, the ratio of phosphorylated/unphosphorylated isoforms was significantly elevated for these proteins. The level of Akt and phospho-Akt was also higher than in controls but the ratio of p-Akt/Akt remained unchanged (Fig. 5C ), suggesting that mTORC1 activation occurs independently of changes in upstream inputs to mTOR such as Akt. Therefore, the results obtained in this tissue model are overall similar to those reported in Mtm1 KO mice, and suggest a hyperactivation of mTORC1 signaling that alters autophagy and the degradation of cellular components. Finally, we analyzed the expression level of genes involved in another atrophic pathway, the UPS. Since this was not described before, first we quantified the mRNA level of key genes (Atrogin-1, Murf1, Nedd4) in muscles from the constitutive Mtm1 KO line. We found an upregulation of atrogin1 and Nedd4 mRNA by 4.3-and 1.6-folds, respectively, in TA of 4-week-old mutant mice (Supplementary Material, Fig. S2 ). However, quantitative RT -PCR analyses from adult Mtm1-deleted muscles revealed a significant and probably compensatory downregulation of these genes at both 3 and 6 months post-injection. Atrogin1 and Murf1 mRNA levels were decreased by 30-40%, suggesting that activation of 
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the UPS pathway is not a prominent feature in myotubularinrelated muscle atrophy during adulthood. In summary, these data indicate that abnormalities in satellite cells, NMJ transmission, autophagy and mTORC1 signaling are consistently observed in models of myotubular myopathy and may play an important role in the pathogenesis of the disease.
Co-delivery of an AAV-Mtm1 vector prevents Cre-mediated pathology
To assess the validity of this tissue model, we investigated whether exogenous myotubularin could prevent the phenotype of Cre-induced Mtm1-deficient muscles. For that purpose, we co-injected an AAV9 vector that carries the Mtm1 cDNA (1.9 × 10 10 vg) and AAV1-eGFP/Cre particles (3 × 10 9 vg) into TA muscle of 3-month-old Mtm1L2 conditional mice. We analyzed the effect of these transgenes 3 months after vector injection, because by that time Cre-mediated Mtm1 deletion resulted in a myopathy. As expected, exon 4 excision occurred only in Cre-injected Mtm1L2 muscles, and delivery of the AAV-Mtm1 vector resulted in increased levels of myotubularin (Supplementary Material, Fig. S4 ). Figure 6 shows that administration of Mtm1 cDNA in mutant muscles was able to prevent the pathological signs of disease, as TA weight, myofiber size and histology were similar to that observed in WT animals. Therefore, these findings confirm that the phenotype resulting from AAV-eGFP/Cre administration in Mtm1 conditional mice is primarily due to myotubularin deficiency.
DISCUSSION
We describe the use of an adeno-associated viral (AAV) vector to deliver Cre recombinase as a novel approach for deleting the Mtm1 gene in adult skeletal muscles. A single intramuscular injection of AAV-eGFP/Cre resulted in recombination between two LoxP sites surrounding Mtm1 exon 4, myotubularin deficiency and a pathology that recapitulated the hallmarks of myotubular myopathy in targeted muscles of conditional Mtm1L2 mice.
Spacio-temporal recombination by administration of Cre-encoding viral particles represents a powerful tool to study gene function. It is less time-consuming and expensive than the common strategy that consists of crossing conditional lines with transgenic mice that express a ligand-activated Cre recombinase, and appears particularly advantageous for the skeletal musculature, as muscles are easily accessible and well-delimitated tissue structures. Since AAV vectors are nontoxic, elicit a minimal immune response and have natural tropism to muscle cells and long-term persistent transgene expression (23), they are well suited for Cre-mediated gene ablation. However, it has been reported that the Cre recombinase has cytotoxic effects at high expression levels because of aberrant activity at 'pseudo-LoxP' sites in mammalian genomes (24) . Therefore, we administrated a low dose of AAV-eGFP/ Cre (3 × 10 9 vg) into the TA muscle of 3-month-old Mtm1L2 mice. At this dose, we did not observe toxic effects, and the level of eGFP-Cre was sufficient to induce Mtm1 exon 4 excision. In addition, since we used a muscle-specific desmin promoter to drive transgene expression, only nuclei from muscle fibers were GFP-positive. This reflects the cellular heterogeneity of the tissue, with nuclei also originating from other cells such as fibroblasts, endothelial and Schwann cells, which were either not transduced by the vector or not expressing the transgene. It explains why myotubularin, a ubiquitously expressed protein, was strongly reduced after vector delivery, but still present in muscle.
Histopathological and functional analyses of Mtm1-deficient adult muscle revealed a progressive centronuclear myopathy with atrophy, presence of fibers with defects in organelle positioning and severe muscle weakness. The percentage of small fibers (diameter ,20 mm) and fibers with internal nuclei increased progressively in TA muscle, reaching 74 and 15%, respectively, 6 months post-injection. At this age, the aspect of Cre-induced mutant TA was similar to that observed in muscles from late-stage Mtm1-deficient mice and in XLMTM patients (7, 8, 11, 25) . NADH-TR staining (reflecting mainly mitochondria) was abnormal, either distributed as a 'necklace' in the subsarcolemal region, as a 'core-like' or in Figure 4 . Decreased muscle strength following AAV-induced myotubularin deficiency during adulthood. The weight (A), total strength (B) and specific force (C) of isolated EDL muscle decreases progressively after AAV delivery in Mtm1L2 mice. Results from muscles 3 and 6 months after PBS (white column) and AAV-Cre (black column) administration are shown (WT, +3 months, n ¼ 5; Mtm1L2, + 3 and + 6 months, n ¼ 9 per condition).
the center of fibers. T-tubules and the associated DHPRa marker were also abnormally located within fibers, and the typical longitudinal L-tubules were present. A striking reduction in muscle force that correlated with pathology progression was observed in these Mtm1-deficient muscles. Defects in excitation -contraction coupling due to triad and T-tubules alterations are thought to underline muscle weakness in myotubular myopathy (7, 11) .
The progressive status of the pathology was previously reported in constitutive (KO) and muscle-specific (mKO) mouse models of the disease (8) , but in these mice, Mtm1 exon 4 deletion occurred constitutively or shortly after birth and the reduction in myofiber size resulted from a defect in muscle growth (hypotrophy) rather than atrophy. Similarly, in knock-in mice carrying a milder Mtm1 C205T mutation, muscle weight was already reduced by 40-50% at 1 month of age, and the pathology evolved over time (9) . Since there is no natural history study for myotubular myopathy, it is unknown whether the disorder is progressive in patients, but this may correlate inversely with disease severity.
Patients that present with the 'classical' neonatal form of XLMTM have poor prognosis but the muscular disorder is considered as nonprogressive, whereas patients with an 'atypical' late-onset form develop mild signs of the disease during early childhood that are slowly progressive (1, 3, 4, 25) . However, it has to be noted that an XLMTM patient with neonatal onset who was biopsied twice in a 3-year interval had an increased proportion of myofibers with central nuclei with age (26) . Therefore, even though disease evolution needs to be better documented in humans, our results in mice clearly show that myotubularin is required for the proper function of adult myofibers but are not conclusive regarding the progressive status of the disease, as temporal deletion of an essential gene would lead per se to a progressive disease development.
We evaluated whether other known cellular and molecular abnormalities associated with myotubularin deficiency, some of which may contribute to muscle atrophy, were found in this tissue model. Constitutive Mtm1 KO mice have defects in satellite cells that correlate with disease evolution (14) . 
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Similarly, we observed that the number of myogenic Pax7 + cells decreased markedly during disease progression in Mtm1L2 Cre-injected muscles. It is not known whether this is a primary or secondary event in XLMTM pathogenesis. Since myogenic Pax7 + cells express desmin (27) , such depletion in our model suggests that the AAV-Cre vector may also be active in satellite cells. Myotubularin deficiency in satellite cells could lead to the activation of caspases and apoptosis, as previously described ex vivo and in vivo (14, 28) . Alternatively, internal disorganization of muscle fibers, myonuclei repositioning and altered membrane remodeling may disturb the interaction/cross-talk between the myofiber and the niche of satellite cells, leading to defects in satellite cell maintenance. We also observed alterations in the expression of acetylcholine receptor subunits that correlated with disease progression in these single-mutant muscles, suggesting that neuromuscular transmission is consistently perturbed in myotubularindeficient myofibers, as described in Mtm1-deficient mice and in patients (13, 29) . A recent study showed that myotubularin deficiency in muscle leads to inefficient autophagy likely due to persistent mTORC1 activation (22) . After Cre-mediated Mtm1 ablation, we also observed increases in mTORC1 downstream effectors, such as p-S6 and p-4EBP1, and an accumulation of LC3-I and LC3-II, indicating that the same molecular events appear in this tissue model and may contribute to muscle atrophy. The role of atrogenes and the UPS in XLMTM-related muscle mass reduction will have to be further explored using the various models, because transcript levels of atrogin1 and Nedd4 were found elevated in muscles from constitutive KO mice, but not in muscles from Cre-injected adult mice and muscle-specific mKO animals at 7 weeks of age, when the pathology is also well established (data not shown), and may relate to differences in disease evolution and severity.
In summary, we have shown that deletion of the Mtm1 gene in a single adult muscle is sufficient to reproduce most histopathological, functional and molecular changes previously observed in mutant mice with myotubular myopathy. Therefore, this novel tissue model of the disease represents an excellent complementary approach to study pathogenesis and therapeutic strategies.
MATERIALS AND METHODS
Animals
Mice were handled according to French and European legislation on animal care and experimentation, and protocols were approved by the institutional Ethics Committee. The conditional Mtm1-floxed mouse line (Mtm1L2, also named BS53.52, C57BL/6 background), which contains two lox-P sites around exon 4, was described previously (8) . WT littermate males were used as controls.
Generation of recombinant AAV vector
An AAV expression plasmid that contains the eGFP fused to the N-terminal part of Cre recombinase under the musclespecific desmin promoter (AAV2/1-pDesmin-eGFP/Cre, named AAV-eGFP/Cre) was constructed. The eGFP-Cre cDNA was kindly provided by Dr D. Metzger, France. Similarly, the AAV-Mtm1 vector was constructed by cloning the mouse Mtm1 cDNA downstream the desmin promoter into the AAV2 genomic backbone. Briefly, recombinant serotype 1 and 9 viral particles were obtained by a tri-transfection procedure from HEK293 cells as previously described (30) . Vector titers were expressed as viral genomes per milliliter (vg/ml).
Intramuscular delivery of viral vectors
Three-month-old Mtm1L2 mice and age-matched WT males were anesthetized by intraperitoneal injection of a mixture of 100 mg/Kg of ketamine (Virbac) and 10 mg/Kg of xylazine (Rompun, Bayer). Muscles from the anterior compartment of distal hind limbs, TA and EDL were injected with either 3 × 10 9 vg of AAV-eGFP/Cre or sterile PBS solution. Muscles were dissected under anesthesia 3 and 6 months after injection and frozen in either liquid nitrogen-cooled isopentane or liquid nitrogen for histological and molecular assays, respectively.
Histological and immunofluorescence analyses
Histology and morphometry Cross-sections (7 mm) of isopentane-frozen TA or EDL muscle were taken midway down the length of the muscle and stained with HE, using standard procedures. The proportion of internalized nuclei was measured from HE-stained sections with the Histolab software (Microvision, Evry, France).
To measure the diameter of myofibers, muscle cross-sections were labeled with a primary antibody against laminin (DAKO) and a secondary antibody which is conjugated with a horseradish protein (HRP)-labeled polymer, and revealed with 3,3 ′ -diaminobenzidine (DAB) according to the manufacturer's instructions (EnVision+ System-HRP rabbit, DAKO). The minor diameter (MinFeret) of each myofiber was measured by using the Ellix software (Microvision, Evry, France).
For NADH-TR reaction, cryosections were incubated with nitroblue tetrazolium (1 mg/ml, Sigma) and b-NADH (0.4 mg/ ml, Sigma) in 50 mM Tris-HCl, pH 7.3, at 578C for 10-15 min.
Immunofluorescence
Detection of eGFP and laminin was performed on muscle cryosections by standard immunofluorescence techniques using laminin (DAKO) and GFP (Abcam) primary antibodies and alexa-conjugated secondary IgG (Molecular probes). For DHRPa immunostaining, sections were boiled for 10 min in PBS and blocked with 3% BSA, incubated with primary antibodies against DHRPa (Pierce) and with biotinylated goat anti-mouse IgG (Southern Biotechnology), followed by incubation with streptavidin/alexa 488 antibody (Molecular Probes). Samples were analyzed using a confocal microscope (Leica, Wetzlar, Germany). Pax 7 immunostaining was modified from Castets et al. (31) by using a biotin/streptavivin/peroxidase labeling procedure according to the manufacturer's instructions (Vectastain, Vector).
Electron microscopy Selective staining of T-tubules in TA muscle and staining of thin (70 nm) sections with uranyl acetate and lead citrate were performed as previously described (11) .
Functional analysis
The isometric contractile properties of EDL muscles were studied in vitro. Measurements were performed according to methods previously detailed (30) . Briefly, muscles were dissected and connected at one end to an electromagnetic puller and at the other end to a force transducer. After equilibration, stimulation (frequency of 125 Hz, train of stimulation of 300 ms) was delivered through electrodes running parallel to the muscle. Tetanus isometric contractions were recorded at L 0 (which corresponds to the length at which maximal tetanus isometric force is observed) and the maximal/absolute isometric tension (P 0 ) was measured. Specific isometric tension (sP 0 ) was calculated by dividing the force by the weight of the muscle.
DNA analysis
Genomic DNA was isolated from TA muscle cryosections (500 mm), using Wizard Genomic DNA Purification Kit (Promega) according to the manufacturer's instructions. PCR amplification of Mtm1 exon 4 was performed at a melting temperature of 558C, with the following primers: glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 5
′ -TTGTGATGGGT GTGAACCAC-3 ′ and 5 ′ -TTCAGCTCTGGGATGACCTT-3 ′ ; and Mtm1 exon 4, 5
′ -AGACAGTGATGCACAGAGAG-3 ′ and 5
′ -ACCCTGCTACTTAGCTGTTG-3 ′ .
Western blotting
Isopentane-frozen TA muscles were cut in 30 mm crosssections and lysed on ice in buffer containing 150 mM NaCl, 10 mM Tris -HCl (pH 7.4), 1 mM EGTA, 1 mM EDTA, 100 mM sodium fluoride, 4 mM sodium pyrophosphate, 2 mM sodium orthovanadate, 1% Triton X-100 and 0.5% IGEPAL supplemented with a complete protease inhibitor cocktail (Roche). Muscle extracts were incubated during 1 h and centrifuged at 48C at 12 000g for 30 min. Protein concentrations in supernatant were determined using the Bio-Rad Protein Assay Kit (Bio-Rad). Proteins were subjected to SDS-PAGE and, after transfer to nitrocellulose membrane, incubated with antibodies directed against mouse myotubularin [p2348 (30) ], GFP (#ab6556, Abcam), GAPDH (#MAB374, Millipore), p62 (#H00008878-M01, Abnova), LC3 (#NB100-2220, Novus Biologics), phospho-S6 Ser235/236 , S6, phospho-Akt Ser473 , Akt, phospho-4E-BP1 Th37/46 and 4E-BP1 (#2211, #2217, #4060, #4691, #9452, #9459, Cell Signaling Technologies). Protein bands were visualized by infrared fluorescence using Odyssey Imaging System (LICOR Biotechnology, Inc.) and quantified by Odyssey Infrared Imaging System Software (Application Software, version 1.2, 2003).
Quantitative RT -PCR analysis
Total RNA was purified from TA muscles using TRIzol reagent (Invitrogen), according to the manufacturer's instructions. RNA concentration was measured by spectrophotometry (OD 260 nm), and RNA integrity was verified by electrophoresis, using GelRed (Biotium). After DNAse treatment (Fermentas), RNA was reverse-transcribed using RevertAid H minus Reverse Transcriptase (Fermentas) in the presence of random primers (Fermentas). Real-time PCR was performed with primers as previously described (13, 14, 31) 
